Lenalidomide

Small molecule

Also known as CC-5013, CDC-501

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma, Follicular Lymphoma, Myelodysplastic Syndromes, Mantle Cell Lymphoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
US
  • Marginal Zone Lymphoma REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
Product first approved 2005Outside this platform's coverageFDA label
JP
  • Treatment of relapsed or refractory multiple myeloma
Product first approved 2010PMDA
EU
  • Multiple myeloma Revlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least...
Product first approved 2007EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (137)
Follicular Lymphoma
NCT06284122 · The Lymphoma Academic Research Organisation
2024-06-07 – 2034-04 · Follicular Lymphoma
What this study did
NCT06149286 · Regeneron Pharmaceuticals
2023-12-28 – 2031-04-30 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
What this study did
NCT07562022 · Sinocelltech Ltd.
2026-06-09 – 2029-06 · Follicular Lymphoma (FL)
What this study did
NCT01476787 · Celgene
2011-12-29 – 2024-04-30 · Follicular Lymphoma
What this study did
Mantle Cell Lymphoma
NCT01865110 · The Lymphoma Academic Research Organisation
2013-11 – 2025-01-31 · Mantle Cell Lymphoma
What this study did
NCT02354313 · Fondazione Italiana Linfomi - ETS
2010-05 – 2019-01 · MANTLE CELL LYMPHOMA
What this study did
NCT01021423 · Celgene
2010-04-01 – 2011-03-01 · Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma
What this study did
Multiple Myeloma
NCT07903506 · Kite, A Gilead Company
2027-02 – 2042-03 · Newly Diagnosed Multiple Myeloma
What this study did
NCT07887672 · Kite, A Gilead Company
2027-01 – 2042-02 · Newly Diagnosed Multiple Myeloma
What this study did
NCT06187441 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2024-05-14 – 2037-12 · Multiple Myeloma
What this study did
NCT07649525 · University of Leeds
2026-07-03 – 2037-06 · Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
What this study did
NCT06932562 · European Myeloma Network B.V.
2025-12-23 – 2036-12 · Multiple Myeloma
What this study did
NCT06918002 · Intergroupe Francophone du Myelome
2025-07-09 – 2036-05 · Multiple Myeloma, Newly Diagnosed
What this study did
NCT07285239 · PrECOG, LLC.
2026-12 – 2034-06 · Multiple Myeloma
What this study did
NCT07764978 · AstraZeneca
2026-06-26 – 2034-05-12 · Newly Diagnosed Multiple Myeloma
What this study did
NCT01863550 · ECOG-ACRIN Cancer Research Group
2013-12-06 – 2034-02-05 · Plasma Cell Myeloma
What this study did
NCT04270409 · Sanofi
2020-06-16 – 2033-10-21 · Plasma Cell Myeloma
What this study did
NCT07671287 · University of Heidelberg Medical Center
2026-06-30 – 2033-01-30 · Multiple Myeloma
What this study did
NCT04483739 · European Myeloma Network B.V.
2020-09-25 – 2032-12-31 · Multiple Myeloma
What this study did
NCT06182774 · Canadian Cancer Trials Group
2024-04-10 – 2032-07-31 · Multiple Myeloma
What this study did
NCT05561387 · SWOG Cancer Research Network
2023-10-12 – 2031-05-30 · Plasma Cell Myeloma
What this study did
NCT03742297 · PETHEMA Foundation
2018-10-22 – 2031-01 · Newly Diagnosed Multiple Myeloma
What this study did
NCT03937635 · ECOG-ACRIN Cancer Research Group
2019-09-16 – 2029-12-31 · Smoldering Plasma Cell Myeloma
What this study did
NCT03710603 · Stichting European Myeloma Network
2018-12-14 – 2029-11 · Multiple Myeloma
What this study did
NCT03948035 · Wuerzburg University Hospital
2018-08-28 – 2029-08 · Newly Diagnosed Multiple Myeloma
What this study did
NCT05558319 · PETHEMA Foundation
2022-11-10 – 2029-04 · Newly Diagnosed Multiple Myeloma
What this study did
A Study of Daratumumabactive not recruiting
NCT05438043 · Janssen Research & Development, LLC
2022-12-15 – 2029-01-31 · Multiple Myeloma
What this study did
NCT03617731 · University of Heidelberg Medical Center
2018-10-18 – 2028-06 · Multiple Myeloma
What this study did
NCT04566328 · ECOG-ACRIN Cancer Research Group
2021-02-24 – 2027-12-31 · Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
What this study did
NCT02659293 · University of Chicago
2016-04-26 – 2027-11 · Multiple Myeloma
What this study did
NCT00098475 · National Cancer Institute (NCI)
2004-11-03 – 2027-10-21 · DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
What this study did
NCT04096066 · Fondazione EMN Italy Onlus
2019-07-01 – 2027-09-01 · Multiple Myeloma, New Diagnosis Tumor
What this study did
NCT00644228 · National Cancer Institute (NCI)
2008-07-28 – 2027-06-10 · DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
What this study did
NCT01169337 · National Cancer Institute (NCI)
2011-01-24 – 2027-05-19 · Light Chain Deposition Disease, Smoldering Multiple Myeloma
What this study did
Phase 2/3 (10)
Multiple Myeloma
NCT07887984 · Alliance for Clinical Trials in Oncology
2026-12-23 – 2053-08-01 · Multiple Myeloma (MM)
What this study did
NCT07428369 · Regeneron Pharmaceuticals
2026-06-05 – 2038-05-21 · Multiple Myeloma (MM)
What this study did
NCT05665140 · University Hopsital Schleswig Holstein Campus Lübeck
2023-02-03 – 2028-10 · Newly Diagnosed Multiple Myeloma
What this study did
NCT03759093 · National University Hospital, Singapore
2023-09-10 – 2025-09-10 · Multiple Myeloma
What this study did
NCT02145598 · Dr. med. Lars-Olof Muegge
2013-08 – 2018-12-31 · Multiple Myeloma
What this study did
NCT02419118 · Vejle Hospital
2015-01 – 2015-10-01 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07068165 · Peking Union Medical College Hospital
2025-07-07 – 2028-08-20 · IgG4 Related Disease
What this study did
NCT01197560 · Celgene
2010-09-02 – 2018-04-05 · Diffuse Large B-cell Lymphoma
What this study did
NCT00120120 · Celgene Corporation
2005-01 – 2007-11 · Radiculopathy
What this study did
NCT00055562 · Celgene Corporation
2003-01 – 2004-12 · Melanoma, Neoplasm Metastasis
What this study did
Phase 2 (504)
Follicular Lymphoma
NCT05848765 · University of Birmingham
2023-09-04 – 2031-11-30 · Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
What this study did
NCT06792825 · Masonic Cancer Center, University of Minnesota
2025-08-07 – 2031-07-08 · Follicular Lymphoma, Marginal Zone Lymphoma
What this study did
NCT07814001 · The Lymphoma Academic Research Organisation
2026-12 – 2031-05 · Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory T-cell/Histiocyte-rich Large B-cell Lymphoma, Refractory Transformed Follicular Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Follicular Lymphoma Grade 3B
What this study did
NCT07585747 · Institute of Hematology & Blood Diseases Hospital, China
2026-04-15 – 2030-12-31 · Follicular Lymphoma
What this study did
NCT07299149 · Institute of Hematology & Blood Diseases Hospital, China
2025-12-25 – 2030-12-25 · Follicular Lymphoma
What this study did
NCT02446457 · M.D. Anderson Cancer Center
2015-07-31 – 2030-04-30 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
What this study did
NCT07418190 · The First Affiliated Hospital with Nanjing Medical University
2026-02-01 – 2029-12-31 · Relapsed/Refractory Follicular Lymphoma
What this study did
NCT05890352 · SWOG Cancer Research Network
2023-09-26 – 2029-12 · Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
What this study did
NCT04404088 · M.D. Anderson Cancer Center
2020-07-16 – 2028-03-01 · Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
What this study did
NCT06151080 · The First Affiliated Hospital of Xiamen University
2023-11-22 – 2027-12-31 · DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
What this study did
NCT04792502 · Brown University
2022-07-14 – 2027-08-31 · Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma
What this study did
NCT06112847 · City of Hope Medical Center
2024-01-24 – 2027-08-10 · Follicular Lymphoma
What this study did
NCT03269669 · National Cancer Institute (NCI)
2018-01-23 – 2027-01-21 · Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
What this study did
NCT05821088 · David Bond, MD
2023-06-29 – 2026-12-31 · Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT06549335 · Ruijin Hospital
2024-12-01 – 2026-12-31 · Follicular Lymphoma
What this study did
NCT02871219 · M.D. Anderson Cancer Center
2016-12-06 – 2024-06-26 · Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Bulky Disease, Fatigue, Fever, Grade 3a Follicular Lymphoma, Night Sweats, Splenomegaly, Weight Loss
What this study did
NCT02532257 · M.D. Anderson Cancer Center
2016-04-11 – 2023-08-15 · Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, CD20 Positive, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
What this study did
NCT01307605 · Swiss Cancer Institute
2011-02-09 – 2023-01-25 · Lymphoma
What this study did
NCT01145495 · National Cancer Institute (NCI)
2010-06-15 – 2022-01-15 · Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
What this study did
NCT03715309 · Ruijin Hospital
2018-11-01 – 2020-11-01 · Follicular Lymphoma
What this study did
NCT00695786 · M.D. Anderson Cancer Center
2008-06-10 – 2020-07-11 · Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage III Small Lymphocytic Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Ann Arbor Stage IV Small Lymphocytic Lymphoma
What this study did
NCT01121757 · Duke University
2010-04 – 2016-01 · Follicular Lymphoma, Marginal Zone Lymphoma
What this study did
NCT01393756 · The Lymphoma Academic Research Organisation
2010-12 – 2015-11 · Follicular Lymphoma
What this study did
Mantle Cell Lymphoma
NCT01415752 · Eastern Cooperative Oncology Group
2012-08-09 – 2031-09 · Lymphoma, Mantle Cell Lymphoma
What this study did
NCT05910801 · Academic and Community Cancer Research United
2024-01-04 – 2030-12-30 · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT07460362 · Peking University Third Hospital
2025-08-11 – 2029-12-30 · MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL)
What this study did
NCT07261163 · Institute of Hematology & Blood Diseases Hospital, China
2025-12-20 – 2029-07-31 · Mantle Cell Lymphoma
What this study did
NCT06504199 · Institute of Hematology & Blood Diseases Hospital, China
2024-07-18 – 2028-12-31 · Mantle Cell Lymphoma
What this study did
NCT03863184 · Weill Medical College of Cornell University
2019-10-11 – 2028-05-30 · Mantle Cell Lymphoma
What this study did
NCT05564052 · Janssen Research & Development, LLC
2022-12-06 – 2024-09-26 · Lymphoma, Mantle-Cell
What this study did
NCT05788289 · Memorial Sloan Kettering Cancer Center
2023-03-14 – 2024-08-01 · Mantle Cell Lymphoma, MCL
What this study did
NCT02633137 · Memorial Sloan Kettering Cancer Center
2015-12-14 – 2023-11-07 · Mantle Cell Lymphoma, Untreated
What this study did
NCT05076097 · Tianjin Medical University Cancer Institute and Hospital
2021-09-30 – 2023-10-15 · Mantle Cell Lymphoma
What this study did
NCT01472562 · Weill Medical College of Cornell University
2011-07-29 – 2023-07-30 · Mantle Cell Lymphoma
What this study did
NCT03891355 · Fondazione Italiana Linfomi - ETS
2019-09-30 – 2022-12-08 · Mantle Cell Lymphoma
What this study did
NCT03019640 · M.D. Anderson Cancer Center
2017-10-10 – 2021-08-16 · Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma
What this study did
NCT03232307 · M.D. Anderson Cancer Center
2019-07-01 – 2021-07-01 · CCND1 Positive, CD20-Positive Neoplastic Cells Present, Mantle Cell Lymphoma
What this study did
NCT00783367 · Abramson Cancer Center at Penn Medicine
2008-07 – 2020-11-23 · Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
What this study did
NCT02460276 · Lund University Hospital
2015-04 – 2019-12-31 · Relapsed/Refractory Mantle Cell Lymphoma
What this study did
NCT00875667 · Celgene
2009-04-30 – 2018-10-09 · Mantle Cell Lymphoma, Lymphoma, Mantle-Cell
What this study did
NCT01737177 · Fondazione Italiana Linfomi - ETS
2012-07-31 – 2017-02-02 · Mantle Cell Lymphoma
What this study did
NCT00609869 · H. Lee Moffitt Cancer Center and Research Institute
2007-10 – 2015-08 · Lymphocytic Leukemia, Mantle Cell Lymphoma
What this study did
NCT00553644 · National Cancer Institute (NCI)
2007-11-15 – 2014-01-21 · Recurrent Mantle Cell Lymphoma
What this study did
NCT00786851 · Fondazione Italiana Linfomi - ETS
2008-07 – 2011-08 · MANTLE CELL LYMPHOMA
What this study did
Multiple Myeloma
NCT07247097 · Massachusetts General Hospital
2026-08-01 – 2035-12-01 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
What this study did
NCT05145400 · UNC Lineberger Comprehensive Cancer Center
2022-02-18 – 2033-05-28 · Multiple Myeloma, Cancer
What this study did
NCT06974786 · SCRI Development Innovations, LLC
2025-08-08 – 2033-04 · Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
What this study did
NCT06910124 · Dickran Kazandjian, MD
2025-12-02 – 2032-12-02 · Multiple Myeloma
What this study did
Phase 1/2 (175)
Follicular Lymphoma
NCT04669171 · Enterome
2021-07-05 – 2034-05-30 · Follicular Lymphoma, Marginal Zone Lymphoma
What this study did
NCT04663347 · Genmab
2020-11-03 – 2027-09-30 · Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
What this study did
NCT05683171 · M.D. Anderson Cancer Center
2023-05-19 – 2027-09-30 · Lymphoma
What this study did
NCT04542824 · Genmab
2020-08-20 – 2027-09 · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT03980171 · Peter MacCallum Cancer Centre, Australia
2019-08-19 – 2026-11 · Follicular Lymphoma
What this study did
NCT04110301 · Beijing Mabworks Biotech Co., Ltd.
2019-11-28 – 2025-05 · Follicular Lymphoma and Marginal Zone Lymphoma
What this study did
NCT04796857 · Huiqiang Huang
2021-03-31 – 2023-03-31 · Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma, EBV-Positive DLBCL, Nos, ALK-Positive Anaplastic Large Cell Lymphoma
What this study did
NCT01995669 · M.D. Anderson Cancer Center
2014-05-27 – 2023-01-23 · Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
What this study did
NCT01582776 · The Lymphoma Academic Research Organisation
2012-10-03 – 2022-05-20 · Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
What this study did
NCT02600897 · Hoffmann-La Roche
2016-03-24 – 2021-12-15 · Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT01076543 · National Cancer Institute (NCI)
2010-04-15 – 2018-09-30 · AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT01180569 · Memorial Sloan Kettering Cancer Center
2010-08 – 2011-05 · Lymphoma, Follicular Lymphoma
What this study did
Mantle Cell Lymphoma
NCT05025800 · M.D. Anderson Cancer Center
2021-10-13 – 2028-03-21 · Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Composite Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome
What this study did
NCT03523975 · City of Hope Medical Center
2018-12-28 – 2027-06-24 · Mantle Cell Lymphoma
What this study did
NCT05861050 · City of Hope Medical Center
2023-08-10 – 2027-02-01 · Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
What this study did
NCT03015896 · David Bond, MD
2017-02-14 – 2026-08-28 · Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT02213913 · University of Chicago
2014-07-29 – 2024-10-29 · Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage 0 Chronic Lymphocytic Leukemia, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
What this study did
NCT02281279 · Mayo Clinic
2016-10 – 2020-10 · B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
What this study did
NCT01075321 · Mayo Clinic
2011-01-10 – 2020-02-13 · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT01035463 · University of Nebraska
2009-11-12 – 2018-07-27 · Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
What this study did
NCT00963534 · Lund University Hospital
2009-09 – 2017-08 · Mantle Cell Lymphoma
What this study did
NCT00633594 · SCRI Development Innovations, LLC
2008-06 – 2016-11 · Mantle Cell Lymphoma
What this study did
NCT00294632 · M.D. Anderson Cancer Center
2006-02 – 2016-02 · Lymphoma
What this study did
NCT00901615 · Lymphoma Study Association
2009-01-06 – 2015-11-23 · Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
What this study did
NCT02983097 · Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
2010-11 – 2015-04-28 · Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant, Burkitt Lymphoma (BL), Aggressive Marginal Zone Lymphoma (MZL)
What this study did
Multiple Myeloma
NCT07600151 · Universitätsklinikum Hamburg-Eppendorf
2026-12-01 – 2036-12-31 · Myeloma Multiple, Myeloma
What this study did
NCT04822337 · Wake Forest University Health Sciences
2021-05-19 – 2032-11 · Multiple Myeloma
What this study did
NCT05583617 · Hoffmann-La Roche
2023-11-14 – 2028-07-31 · Multiple Myeloma
What this study did
NCT06087653 · Starton Therapeutics, Inc
2023-10-02 – 2028-03-31 · Multiple Myeloma
What this study did
NCT07210047 · HuniLife Biotechnology, Inc.
2025-08-18 – 2028-01-31 · Multiple Myeloma Refractory
What this study did
NCT01297764 · Hackensack Meridian Health
2011-04 – 2027-06 · Multiple Myeloma
What this study did
NCT02343042 · Karyopharm Therapeutics Inc
2015-10 – 2027-04 · Multiple Myeloma
What this study did
NCT04068597 · CellCentric Ltd.
2019-08-09 – 2027-03-31 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
What this study did
NCT04126200 · GlaxoSmithKline
2019-10-07 – 2027-03-11 · Multiple Myeloma
What this study did
NCT07150091 · GlaxoSmithKline
2022-07-19 – 2027-03-11 · Multiple Myeloma
What this study did
NCT00378105 · Dana-Farber Cancer Institute
2006-09 – 2026-12 · Multiple Myeloma
What this study did
NCT01054196 · Weill Medical College of Cornell University
2010-08 – 2026-12 · Multiple Myeloma
What this study did
NCT05573802 · Hellenic Society of Hematology
2023-07-14 – 2026-10-31 · Multiple Myeloma, Neoplasms, Neoplasm, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
What this study did
NCT05280275 · Hellenic Society of Hematology
2022-04-13 – 2026-03-15 · Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
What this study did
NCT05422027 · Xia Zhongjun
2022-07-25 – 2025-12-31 · Multiple Myeloma
What this study did
NCT01668719 · SWOG Cancer Research Network
2012-11 – 2025-09-22 · DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
What this study did
NCT01615029 · Janssen Research & Development, LLC
2012-06-26 – 2024-10-23 · Multiple Myeloma
What this study did
NCT02937571 · Memorial Sloan Kettering Cancer Center
2016-10 – 2024-10-08 · Multiple Myeloma
What this study did
NCT04674514 · Ascentage Pharma Group Inc.
2021-04-13 – 2024-05 · Multiple Myeloma
What this study did
NCT01755975 · Memorial Sloan Kettering Cancer Center
2012-12 – 2023-10 · Multiple Myeloma, Non-Hodgkin's Lymphoma
What this study did
NCT02685826 · Celgene
2016-04-25 – 2022-09-06 · Multiple Myeloma
What this study did
Phase 1 (203)
Follicular Lymphoma
NCT05867030 · Innovent Biologics (Suzhou) Co. Ltd.
2023-07-28 – 2033-04-30 · Follicular Lymphoma
What this study did
NCT01829568 · National Cancer Institute (NCI)
2013-06-26 – 2027-06-06 · Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
What this study did
NCT02992522 · Beth Christian
2017-02-21 – 2027-04-15 · B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, B-Cell
What this study did
NCT04447716 · Thomas Jefferson University
2020-10-16 – 2027-03 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma
What this study did
NCT01953692 · Merck Sharp & Dohme LLC
2013-11-22 – 2020-06-26 · Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Primary Mediastinal B-Cell Lymphoma
What this study did
NCT01644799 · Alliance for Clinical Trials in Oncology
2013-08-02 – 2017-05 · Recurrent Follicular Lymphoma
What this study did
Mantle Cell Lymphoma
NCT07697339 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2026-07-10 – 2028-12-01 · Mantle Cell Lymphoma
What this study did
NCT06192888 · Memorial Sloan Kettering Cancer Center
2024-01-08 – 2028-01-08 · Mantle Cell Lymphoma, MCL
What this study did
NCT01955499 · National Cancer Institute (NCI)
2013-09-24 – 2027-05-06 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma
What this study did
NCT02446236 · Hackensack Meridian Health
2015-06-18 – 2027-01 · Mantle Cell Lymphoma
What this study did
NCT02568553 · National Cancer Institute (NCI)
2016-11-15 – 2025-11-24 · Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mediastinal Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Gray-Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Mediastinal Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
What this study did
NCT04903197 · Novartis Pharmaceuticals
2022-01-24 – 2025-02-24 · Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
What this study did
NCT04578600 · Joseph Tuscano
2020-10-23 – 2025-02-21 · Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
What this study did
NCT04635683 · Yazeed Sawalha
2022-09-30 – 2024-12-31 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia
What this study did
NCT01729104 · M.D. Anderson Cancer Center
2013-04-25 – 2018-10-03 · Lymphoma
What this study did
NCT01838434 · Alliance for Clinical Trials in Oncology
2013-10-17 – 2017-05-01 · Relapsed/Refractory Mantle Cell Lymphoma
What this study did
NCT01744912 · TG Therapeutics, Inc.
2012-11-21 – 2014-02-07 · Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia
What this study did
NCT01254578 · National Cancer Institute (NCI)
2010-11-24 – 2012-11-09 · Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Promyelocytic Leukemia With PML-RARA, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Alkylating Agent-Related Acute Myeloid Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Post-Transplant Lymphoproliferative Disorder, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Richter Syndrome, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT01045928 · Case Comprehensive Cancer Center
2010-01 – 2012-03 · Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT01116154 · City of Hope Medical Center
2010-05 – 2010-08 · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
What this study did
Multiple Myeloma
NCT06768489 · Janssen Research & Development, LLC
2024-12-04 – 2029-06-29 · Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
What this study did
NCT07341867 · Andrew Hantel, MD
2026-07-30 – 2029-03-31 · Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
What this study did
NCT06209606 · Oncotherapeutics
2022-12-08 – 2029-02 · Multiple Myeloma
What this study did
NCT05846880 · Amany Keruakous, MD, MS.
2024-12-01 – 2028-05 · Multiple Myeloma
What this study did
NCT04091126 · GlaxoSmithKline
2019-12-18 – 2028-03-10 · Multiple Myeloma
What this study did
NCT05050097 · Janssen Research & Development, LLC
2021-09-22 – 2027-12-31 · Multiple Myeloma
What this study did
NCT01562405 · Massachusetts General Hospital
2012-05 – 2027-12 · Multiple Myeloma
What this study did
NCT04722146 · Janssen Research & Development, LLC
2021-03-12 – 2027-10-13 · Multiple Myeloma
What this study did
NCT02886065 · Massachusetts General Hospital
2017-03-07 – 2027-02-15 · Smoldering Multiple Myeloma
What this study did
NCT03110822 · Oncotherapeutics
2017-02-01 – 2027-02 · Multiple Myeloma
What this study did
NCT02334865 · Roswell Park Cancer Institute
2017-04-13 – 2026-12-19 · Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
What this study did
NCT03070327 · Memorial Sloan Kettering Cancer Center
2017-02-27 – 2026-10-06 · Multiple Myeloma
What this study did
NCT03984097 · Takeda
2019-07-29 – 2026-03-25 · Multiple Myeloma
What this study did
NCT03631043 · M.D. Anderson Cancer Center
2018-12-21 – 2025-12-10 · Smoldering Plasma Cell Myeloma
What this study did
NCT05308654 · AbbVie
2022-05-17 – 2025-12 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT03702725 · Alliance Foundation Trials, LLC.
2019-08-29 – 2024-10-04 · Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
What this study did
NCT03031730 · National Cancer Institute (NCI)
2018-06-14 – 2024-07-24 · Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05556616 · Teva Branded Pharmaceutical Products R&D LLC
2023-01-12 – 2024-06-04 · Multiple Myeloma
What this study did
NCT04892264 · Mayo Clinic
2021-06-03 – 2024-03-18 · Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT03269136 · Pfizer
2017-11-29 – 2024-01-19 · Multiple Myeloma
What this study did
NCT01998971 · Janssen Research & Development, LLC
2014-02-18 – 2024-01-11 · Multiple Myeloma
What this study did
NCT04519476 · Oncotherapeutics
2020-11-01 – 2023-12-29 · Refractory Multiple Myeloma
What this study did
NCT02697344 · Mayo Clinic
2016-04-14 – 2023-12-20 · Recurrent Plasma Cell Myeloma
What this study did
NCT05641324 · Anaveon AG
2023-02-10 – 2023-07-12 · Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease, Hematologic Diseases
What this study did
NCT01749969 · Sanofi
2013-02-06 – 2023-06-20 · Plasma Cell Myeloma
What this study did
Phase 4 (18)
Multiple Myeloma
NCT03829371 · University of Turin, Italy
2019-01-03 – 2030-01-03 · Multiple Myeloma
What this study did
Isa-VRD in TIE HRMMnot yet recruiting
NCT07334535 · Peking Union Medical College Hospital
2026-01-30 – 2029-01 · Multiple Myeloma
What this study did
NCT07709884 · The First Affiliated Hospital of Soochow University
2026-07-01 – 2028-12-31 · Newly Diagnosed Multiple Myeloma, T(11;14), Sotoclax, Carfilzomib
What this study did
NCT05722405 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-01 – 2028-07-31 · Multiple Myeloma
What this study did
NCT06409702 · The First Affiliated Hospital of Soochow University
2024-06-12 – 2027-12-31 · Newly Diagnosed, High Risk, MRD, Multiple Myeloma
What this study did
NCT07025005 · Tanta University
2025-08-30 – 2026-09-30 · Peripheral Neuropathy, Multiple Myeloma, Neoplasms
What this study did
NCT03934684 · Amgen
2019-09-16 – 2025-06-27 · Relapsed Refractory Multiple Myeloma
What this study did
NCT01731886 · Columbia University
2012-09 – 2017-04-11 · Multiple Myeloma
What this study did
Myelodysplastic Syndromes
NCT06004765 · Peking Union Medical College Hospital
2023-08 – 2025-08 · Myelodysplastic Syndromes
What this study did
Other / comorbidity
NCT05598580 · First Affiliated Hospital of Zhejiang University
2022-11-20 – 2024-11 · HIV Infections
What this study did
NCT04038411 · Mingzhi Zhang
2019-04-01 – 2022-04-01 · NK/T Cell Lymphoma
What this study did
NCT04361643 · Hospital Universitario Getafe
2020-10-27 – 2021-12-31 · COVID-19
What this study did
NCT04040491 · Mingzhi Zhang
2019-09-01 – 2021-09-01 · Peripheral T-cell Lymphoma
What this study did
NCT01198054 · PETHEMA Foundation
2011-01 – 2013-02 · AML
What this study did
NCT01408199 · Hospital Universitari Vall d'Hebron Research Institute
2010-01 – 2011-08 · Cutaneous Lupus
What this study did
Early phase / not applicable (22)
Multiple Myeloma
NCT05889221 · Poitiers University Hospital
2023-10-23 – 2028-09-01 · Multiple Myeloma, Myeloma Multiple, Myeloma
What this study did
NCT06697483 · Peking University People's Hospital
2024-12-01 – 2027-12-31 · Multiple Myeloma
What this study did
NCT05477797 · RenJi Hospital
2023-02-16 – 2026-01-15 · Progression Free Survival, Overall Survival, Maintenance
What this study did
NCT04872023 · Rennes University Hospital
2021-07-29 – 2023-01-27 · Multiple Myeloma
What this study did
NCT01050790 · Virginia Commonwealth University
2010-01 – 2016-09 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07299331 · Zhengzhou University
2026-01-01 – 2031-04-30 · Marginal Zone Lymphoma(MZL)
What this study did
NCT07072221 · The First Affiliated Hospital of Soochow University
2024-11-01 – 2029-11-01 · Peripheral T-cell Lymphoma
What this study did
NCT05449548 · Peking Union Medical College Hospital
2023-04-01 – 2026-12-31 · Oral Ulcer
What this study did
NCT07184424 · Beijing Tsinghua Chang Gung Hospital
2023-05-24 – 2025-04-30 · HCC - Hepatocellular Carcinoma
What this study did
NCT05784987 · The First Affiliated Hospital with Nanjing Medical University
2023-04-15 – 2025-01-01 · Diffuse Large B-cell Lymphoma
What this study did
NCT04432402 · The First Affiliated Hospital with Nanjing Medical University
2020-06-14 – 2024-12-31 · Diffuse Large B Cell Lymphoma
What this study did
NCT05797948 · The First Affiliated Hospital of Soochow University
2022-07-01 – 2024-06-30 · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
What this study did
NCT05058755 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2021-09-17 – 2023-12-30 · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
What this study did
NCT05488327 · Jiangxi Provincial People's Hopital
2022-08-01 – 2023-09-01 · Dermatomyositis
What this study did
NCT04835220 · W.G. Bill Hefner Medical Center
2021-03-26 – 2023-06-20 · Medication Compliance
What this study did
NCT01927718 · M.D. Anderson Cancer Center
2014-01 – 2016-11 · Myeloma
What this study did
NCT00907452 · Intergroupe Francophone du Myelome
2009-07-29 – 2016-07-14 · Myeloma
What this study did
NCT02525250 · Institut Paoli-Calmettes
2012-12 – 2015-01 · Acute Myeloid Leukemia or Myelodysplasic Syndrome
What this study did
NCT01649791 · Roswell Park Cancer Institute
2010-01 – 2014-10 · B-cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
What this study did
NCT00890552 · Stanford University
2009-04 – 2012-10 · Leukemia, Amyloidosis
What this study did
NCT00633945 · University of Pennsylvania
2007-11 – 2009-10 · Cutaneous Lupus Erythematosus (CLE)
What this study did
Used as active comparator (28)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (17)
Follicular Lymphoma
NCT06313996 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2024-03-29 – 2031-10-16 · Relapsed or Refractory Follicular Lymphoma
What this study did
NCT05888493 · Novartis Pharmaceuticals
2023-10-02 – 2031-02-20 · Follicular Lymphoma (FL)
What this study did
NCT05371093 · Kite, A Gilead Company
2022-09-22 – 2030-10 · Relapsed/Refractory Follicular Lymphoma
What this study did
NCT05100862 · BeOne Medicines
2022-03-10 – 2030-06 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
What this study did
Mantle Cell Lymphoma
NCT06084936 · Hoffmann-La Roche
2023-10-22 – 2028-03-31 · Lymphoma
What this study did
Multiple Myeloma
NCT04071457 · SWOG Cancer Research Network
2019-08-13 – 2040-07-01 · Multiple Myeloma
What this study did
NCT05827016 · Bristol-Myers Squibb
2023-06-22 – 2036-01-01 · Multiple Myeloma
What this study did
NCT05317416 · Pfizer
2022-03-25 – 2029-10-31 · Multiple Myeloma
What this study did
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf
2023-03-03 – 2025-03-21 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07753369 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2026-08 – 2030-12 · Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia
What this study did
NCT06082102 · Beijing InnoCare Pharma Tech Co., Ltd.
2023-12-19 – 2030-02-25 · Relapsed/Refractory Marginal Zone Lymphoma
What this study did
NCT01659658 · Millennium Pharmaceuticals, Inc.
2012-12-26 – 2022-07-11 · Relapsed or Refractory Systemic Light Chain Amyloidosis
What this study did
Phase 2/3 (3)
Multiple Myeloma
NCT06324266 · Jinling Hospital, China
2023-04-16 – 2025-12-31 · Newly Diagnosed Multiple Myeloma
What this study did
Other / comorbidity
NCT07917754 · Merck Sharp & Dohme LLC
2026-12-13 – 2037-03-13 · Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma
What this study did
Phase 2 (5)
Multiple Myeloma
NCT07764861 · Innovent Biologics (Suzhou) Co. Ltd.
2026-08-15 – 2031-06-30 · Multiple Myeloma
What this study did
NCT05469893 · Irene Ghobrial, MD
2022-08-10 – 2030-07-31 · High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
What this study did
NCT06169215 · National Cancer Institute (NCI)
2024-07-23 – 2027-09-23 · Multiple Myeloma
What this study did
NCT02891811 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2017-03-10 – 2024-03-28 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07189065 · Guangzhou Lupeng Pharmaceutical Company LTD.
2025-11-27 – 2028-12-31 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
Phase 1 (2)
Multiple Myeloma
NCT01711671 · Leap Therapeutics, Inc.
2013-05 – 2015-07 · Multiple Myeloma
What this study did
NCT00884546 · Bristol-Myers Squibb
2009-07 – 2012-03 · Advanced Cancer, Various, NOS
What this study did
Phase 4 (1)
Multiple Myeloma
NCT04217967 · Peking Union Medical College Hospital
2019-09-24 – 2024-06-30 · Multiple Myeloma
What this study did
Appears in other studies (14)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (9)
Follicular Lymphoma
NCT07355283 · ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
2026-02 – 2030-10 · Relapsed/Refractory Follicular Lymphoma
What this study did
Multiple Myeloma
NCT01208662 · Paul Richardson, MD
2010-09 – 2026-12 · Multiple Myeloma
What this study did
NCT01564537 · Takeda
2012-08-01 – 2022-02-08 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
What this study did
Other / comorbidity
NCT00843882 · National Cancer Institute (NCI)
2009-04-20 – 2027-05-28 · Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
What this study did
NCT04404283 · Seagen, a wholly owned subsidiary of Pfizer
2020-08-20 – 2026-12-31 · Diffuse Large B-cell Lymphoma
What this study did
Phase 2 (5)
Mantle Cell Lymphoma
NCT01419795 · Fred Hutchinson Cancer Center
2012-05 – 2013-09 · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
What this study did
Multiple Myeloma
NCT03376477 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-09-23 – 2025-05-30 · Multiple Myeloma
What this study did
NCT02389517 · University of Chicago
2015-03-02 – 2024-01 · Plasma Cell Myeloma, Residual Disease
What this study did
Other / comorbidity
NCT05186558 · The First Affiliated Hospital with Nanjing Medical University
2022-05-15 – 2026-02-15 · Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type
What this study did
NCT04842487 · Sun Yat-sen University
2021-04-10 – 2023-12-30 · DLBCL
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lenalidomide: this drugApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech)Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BelantamabPhase 1/2Monoclonal antibodyBCMAnot yet gradedNo reviewed efficacy summary in this indication
CT071Phase 1/2Cell therapyGPRC5Dnot yet gradedNo reviewed efficacy summary in this indication
EltanexorPhase 1/2—XPO1 (exportin-1)Weak signalNo reviewed efficacy summary in this indication
ICP-490Phase 1/2Small moleculeCereblon E3 ubiquitin-ligaseWeak signalNo reviewed efficacy summary in this indication
PirtobrutinibPhase 1Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
TQB3820
Phase 1(overall)
Small moleculeCereblon E3 ubiquitin-ligase, Cereblon E3 ubiquitin-ligaseWeak signalNo reviewed efficacy summary in this indication

Large race: only the 67 furthest-along competitors are listed; 100 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(196 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lenalidomide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (16)
November 2026 (4)
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2026-11 · NCT03980171 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06517017 · CT.gov ↗
What to watch
Phase 2Diffuse Large B Cell LymphomaNot yet recruiting
Est. primary completion 2026-11 · NCT06669143 · CT.gov ↗
What to watch
December 2026 (12)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2026-12 · NCT01562405 · CT.gov ↗
What to watch
Phase 1NeuroblastomaActive not recruiting
Est. primary completion 2026-12 · NCT02573896 · CT.gov ↗
What to watch
Phase 2Myeloma, MultipleActive not recruiting
Est. primary completion 2026-12 · NCT04009109 · CT.gov ↗
What to watch
Phase 2Plasma Cell LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT05979363 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2026-12-01 · NCT06549335 · CT.gov ↗
What to watch
Phase 1/2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2026-12-23 · NCT05950165 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-28 · NCT03729804 · CT.gov ↗
What to watch
Early phase / not applicableOral UlcerRecruiting
Est. primary completion 2026-12-30 · NCT05449548 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT01863550 · CT.gov ↗
What to watch
Phase 1/2CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT05351593 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT06504199 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MyelomaRecruiting
Est. primary completion 2026-12-31 · NCT06697483 · CT.gov ↗
What to watch
2027 (68)
January 2027 (4)
Phase 1Hematological Malignancy, Solid TumorRecruiting
Est. primary completion 2027-01 · NCT05828459 · CT.gov ↗
What to watch
Phase 2Large B-cell LymphomaRecruiting
Est. primary completion 2027-01 · NCT06760156 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaActive not recruiting
Est. primary completion 2027-01-03 · NCT03829371 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-01-16 · NCT04978584 · CT.gov ↗
What to watch
February 2027 (6)
Phase 2Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-02 · NCT05583071 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗
What to watch
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-02-01 · NCT05861050 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-15 · NCT02886065 · CT.gov ↗
What to watch
Phase 2Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder …Recruiting
Est. primary completion 2027-02-18 · NCT06723457 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Double Expressor DLBCL, ELDERLY PEOPLE, Unfit, New-diagnosis DLBCLRecruiting
Est. primary completion 2027-03-11 · NCT07884708 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
Phase 2Solitary PlasmacytomaRecruiting
Est. primary completion 2027-03-31 · NCT06863584 · CT.gov ↗
What to watch
April 2027 (7)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT05558319 · CT.gov ↗
What to watch
Phase 2Central Nervous System LymphomaRecruiting
Est. primary completion 2027-04-01 · NCT05260619 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-05 · NCT03319667 · CT.gov ↗
What to watch
Phase 2B-cell Non-Hodgkin's LymphomaActive not recruiting
Est. primary completion 2027-04-06 · NCT07081022 · CT.gov ↗
What to watch
Phase 2Rosai-Dorfman DiseaseRecruiting
Est. primary completion 2027-04-12 · NCT07187167 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-30 · NCT02420860 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-05-31 · NCT06087653 · CT.gov ↗
What to watch
June 2027 (5)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT01297764 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-06 · NCT05572229 · CT.gov ↗
What to watch
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-06-24 · NCT03523975 · CT.gov ↗
What to watch
Phase 1Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 InfectionRecruiting
Est. primary completion 2027-06-30 · NCT04301076 · CT.gov ↗
What to watch
Phase 1Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma …Recruiting
Est. primary completion 2027-06-30 · NCT06015880 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07 · NCT03556332 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-07-31 · NCT07261163 · CT.gov ↗
What to watch
August 2027 (10)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT02538198 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT04497961 · CT.gov ↗
What to watch
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT05665140 · CT.gov ↗
What to watch
Phase 1Primary Diffuse Large B-Cell Lymphoma of the Central Nervous SystemActive not recruiting
Est. primary completion 2027-08-01 · NCT04609046 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaActive not recruiting
Est. primary completion 2027-08-10 · NCT06112847 · CT.gov ↗
What to watch
Phase 1Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2027-08-10 · NCT07697339 · CT.gov ↗
What to watch
Phase 1/2Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt LymphomaRecruiting
Est. primary completion 2027-08-12 · NCT03223610 · CT.gov ↗
What to watch
Phase 2Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHLRecruiting
Est. primary completion 2027-08-19 · NCT05615636 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-08-31 · NCT04792502 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-08-31 · NCT06151080 · CT.gov ↗
What to watch
September 2027 (8)
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2027-09 · NCT04542824 · CT.gov ↗
What to watch
Phase 3Marginal Zone LymphomaRecruiting
Est. primary completion 2027-09 · NCT06006117 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-01 · NCT04096066 · CT.gov ↗
What to watch
Phase 1/2EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir, Chidamide, LenalidomideNot yet recruiting
Est. primary completion 2027-09-01 · NCT07133763 · CT.gov ↗
What to watch
Phase 1/2Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide, LenalidomideNot yet recruiting
Est. primary completion 2027-09-01 · NCT07133776 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-09-08 · NCT04635189 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2027-09-30 · NCT04663347 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2027-09-30 · NCT05683171 · CT.gov ↗
What to watch
October 2027 (5)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT03004287 · CT.gov ↗
What to watch
Phase 1/2B-Cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10 · NCT05201248 · CT.gov ↗
What to watch
Phase 2Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib, Lenalidomide, Frail ElderlyRecruiting
Est. primary completion 2027-10-01 · NCT07839247 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-10-09 · NCT07789522 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-10-09 · NCT07828522 · CT.gov ↗
What to watch
November 2027 (4)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-11 · NCT02659293 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaRecruiting
Est. primary completion 2027-11-30 · NCT06409702 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-11-30 · NCT07210047 · CT.gov ↗
What to watch
December 2027 (13)
Phase 1/2Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome …Active not recruiting
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT04891809 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT06461988 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT07297329 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-12-30 · NCT07460362 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03376672 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05091372 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05776979 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06441097 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-cell Lymphoma, Relapsed and RefractoryRecruiting
Est. primary completion 2027-12-31 · NCT06651853 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT07418190 · CT.gov ↗
What to watch
2028 (47)
January 2028 (3)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2028-01-01 · NCT06744894 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma(MZL)Recruiting
Est. primary completion 2028-01-01 · NCT07448324 · CT.gov ↗
What to watch
Phase 1Mantle Cell LymphomaActive not recruiting
Est. primary completion 2028-01-08 · NCT06192888 · CT.gov ↗
What to watch
March 2028 (6)
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2028-03 · NCT06508658 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-03-01 · NCT04404088 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2028-03-21 · NCT05025800 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07341867 · CT.gov ↗
What to watch
April 2028 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-04-28 · NCT07299149 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-04-30 · NCT06803693 · CT.gov ↗
What to watch
May 2028 (4)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-05 · NCT05846880 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-05 · NCT07485647 · CT.gov ↗
What to watch
Phase 3Follicular LymphomaRecruiting
Est. primary completion 2028-05 · NCT07562022 · CT.gov ↗
What to watch
Phase 1Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome, Recurrent Transformed Mycosis Fungoides, Refractory Mycosis Fungoides …Not yet recruiting
Est. primary completion 2028-05-16 · NCT07926893 · CT.gov ↗
What to watch
June 2028 (6)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2028-06 · NCT03617731 · CT.gov ↗
What to watch
Phase 1/2HIV (Human Immunodeficiency Virus), HIV -1 InfectionNot yet recruiting
Est. primary completion 2028-06 · NCT07384624 · CT.gov ↗
What to watch
Phase 2Malignant Plasma Cell NeoplasmsNot yet recruiting
Est. primary completion 2028-06 · NCT07560449 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma(MZL)Recruiting
Est. primary completion 2028-06-01 · NCT07208981 · CT.gov ↗
What to watch
Phase 2Leukemia, LymphomaActive not recruiting
Est. primary completion 2028-06-30 · NCT01446133 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2028-06-30 · NCT07639138 · CT.gov ↗
What to watch
July 2028 (4)
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2028-07 · NCT07334535 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2028-07 · NCT07814001 · CT.gov ↗
What to watch
Phase 2/3IgG4 Related DiseaseRecruiting
Est. primary completion 2028-07-20 · NCT07068165 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-07-31 · NCT05583617 · CT.gov ↗
What to watch
August 2028 (2)
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-08-10 · NCT06522555 · CT.gov ↗
What to watch
Phase 1Lymphoma, Non-HodgkinRecruiting
Est. primary completion 2028-08-31 · NCT07308132 · CT.gov ↗
What to watch
September 2028 (3)
Phase 3DLBCLRecruiting
Est. primary completion 2028-09 · NCT06521255 · CT.gov ↗
What to watch
Phase 2High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma …Recruiting
Est. primary completion 2028-09-01 · NCT06649812 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Diffuse Large B Cell LymphomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT06516978 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell Lymphoma (DLBCL)Not yet recruiting
Est. primary completion 2028-10-31 · NCT07917624 · CT.gov ↗
What to watch
November 2028 (5)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2028-11 · NCT06284122 · CT.gov ↗
What to watch
Phase 2Primary CNS LymphomaRecruiting
Est. primary completion 2028-11-02 · NCT04627753 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2028-11-02 · NCT07735637 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-11-30 · NCT06931704 · CT.gov ↗
What to watch
December 2028 (9)
Phase 2Diffuse Large B Cell Lymphoma (DLBCL)Not yet recruiting
Est. primary completion 2028-12-01 · NCT07938619 · CT.gov ↗
What to watch
Phase 3DLBCL - Diffuse Large B Cell LymphomaRecruiting
Est. primary completion 2028-12-15 · NCT06220032 · CT.gov ↗
What to watch
Phase 2Large B-cell Lymphoma, TP53Recruiting
Est. primary completion 2028-12-30 · NCT07240194 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma(MZL)Recruiting
Est. primary completion 2028-12-31 · NCT06793189 · CT.gov ↗
What to watch
Phase 2Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli,SBLPNRecruiting
Est. primary completion 2028-12-31 · NCT07165769 · CT.gov ↗
What to watch
Phase 2Large B-Cell Lymphoma (LBCL)Recruiting
Est. primary completion 2028-12-31 · NCT07514169 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Diffuse Large B Cell LymphomaActive not recruiting
Est. primary completion 2028-12-31 · NCT07621406 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07709884 · CT.gov ↗
What to watch
Phase 2Peripheral T-Cell Lymphoma RefractoryNot yet recruiting
Est. primary completion 2028-12-31 · NCT07913594 · CT.gov ↗
What to watch
2029 (25)
January 2029 (4)
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2029-01 · NCT06665217 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-01-02 · NCT06768489 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-01-31 · NCT05438043 · CT.gov ↗
What to watch
February 2029 (2)
Phase 3Cutaneous Lupus Erythematosus (CLE)Not yet recruiting
Est. primary completion 2029-02-01 · NCT06965244 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-02-14 · NCT04923893 · CT.gov ↗
What to watch
April 2029 (2)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2029-04 · NCT04822337 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-04-15 · NCT07830485 · CT.gov ↗
What to watch
May 2029 (4)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-05-05 · NCT07891923 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2029-05-30 · NCT04669171 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2029-05-31 · NCT05848765 · CT.gov ↗
What to watch
Phase 2Large B-Cell Lymphoma (LBCL)Not yet recruiting
Est. primary completion 2029-05-31 · NCT07594899 · CT.gov ↗
What to watch
June 2029 (3)
Phase 2Plasma Cell Leukemia (PCL)Recruiting
Est. primary completion 2029-06-30 · NCT07652905 · CT.gov ↗
What to watch
Phase 2Large B-Cell Lymphoma (LBCL)Not yet recruiting
Est. primary completion 2029-06-30 · NCT07717177 · CT.gov ↗
What to watch
Phase 1Diffuse Large B-Cell Lymphoma (DLBCL)Not yet recruiting
Est. primary completion 2029-06-30 · NCT07906080 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2029-07-08 · NCT06792825 · CT.gov ↗
What to watch
August 2029 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-08 · NCT03948035 · CT.gov ↗
What to watch
Early phase / not applicablePeripheral T-cell LymphomaRecruiting
Est. primary completion 2029-08-01 · NCT07072221 · CT.gov ↗
What to watch
December 2029 (7)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2029-12 · NCT05409066 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-cell LymphomaRecruiting
Est. primary completion 2029-12 · NCT06664411 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2029-12-01 · NCT05890352 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2029-12-30 · NCT05910801 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-12-31 · NCT03937635 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-12-31 · NCT06207799 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07585747 · CT.gov ↗
What to watch
2030 (12)
April 2030 (2)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-04-01 · NCT07029776 · CT.gov ↗
What to watch
Phase 1/2Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides …Recruiting
Est. primary completion 2030-04-14 · NCT03011814 · CT.gov ↗
What to watch
July 2030 (2)
Phase 3Follicular LymphomaNot yet recruiting
Est. primary completion 2030-07 · NCT07719855 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-cell LymphomaRecruiting
Est. primary completion 2030-07-30 · NCT06503263 · CT.gov ↗
What to watch
September 2030 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2030-09-06 · NCT04246086 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-09-30 · NCT06997081 · CT.gov ↗
What to watch
October 2030 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2030-10-14 · NCT04270409 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2030-10-18 · NCT05623020 · CT.gov ↗
What to watch
December 2030 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-12 · NCT05344833 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-12-01 · NCT07247097 · CT.gov ↗
What to watch
Phase 3Immunoglobulin G4-Related DiseaseNot yet recruiting
Est. primary completion 2030-12-31 · NCT07719543 · CT.gov ↗
What to watch
2031 (10)
January 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-01 · NCT06187441 · CT.gov ↗
What to watch
February 2031 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2031-02-14 · NCT07671287 · CT.gov ↗
What to watch
April 2031 (4)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-04-28 · NCT06679101 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-04-30 · NCT05552222 · CT.gov ↗
What to watch
Phase 3Follicular LymphomaRecruiting
Est. primary completion 2031-04-30 · NCT06149286 · CT.gov ↗
What to watch
Early phase / not applicableMarginal Zone Lymphoma(MZL)Not yet recruiting
Est. primary completion 2031-04-30 · NCT07299331 · CT.gov ↗
What to watch
May 2031 (2)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-05-30 · NCT05561387 · CT.gov ↗
What to watch
Phase 2Primary Central Nervous System Lymphoma and Primary Vitreoretinal LymphomaNot yet recruiting
Est. primary completion 2031-05-31 · NCT05901324 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-11 · NCT07285239 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Large B Cell LymphomaRecruiting
Est. primary completion 2031-12-27 · NCT07126236 · CT.gov ↗
What to watch
2032 (5)
January 2032 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2032-01-31 · NCT06182774 · CT.gov ↗
What to watch
November 2032 (3)
Phase 2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2032-11 · NCT05283720 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-11 · NCT06974786 · CT.gov ↗
What to watch
Phase 2Plasma Cell LeukemiaRecruiting
Est. primary completion 2032-11-06 · NCT07605416 · CT.gov ↗
What to watch
December 2032 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2032-12-02 · NCT06910124 · CT.gov ↗
What to watch
2033 (5)
May 2033 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2033-05-28 · NCT05145400 · CT.gov ↗
What to watch
June 2033 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2033-06 · NCT05257083 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-06 · NCT07649525 · CT.gov ↗
What to watch
August 2033 (1)
Phase 2/3Multiple MyelomaNot yet recruiting
Est. primary completion 2033-08-01 · NCT07887984 · CT.gov ↗
What to watch
September 2033 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2033-09 · NCT05259839 · CT.gov ↗
What to watch
2035 (2)
February 2035 (1)
Phase 1/2Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, PrimaryActive not recruiting
Est. primary completion 2035-02-02 · NCT04446962 · CT.gov ↗
What to watch
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch
2036 (3)
May 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-05 · NCT06918002 · CT.gov ↗
What to watch
September 2036 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2036-09-30 · NCT07600151 · CT.gov ↗
What to watch
December 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-12 · NCT06932562 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2037-11 · NCT06191744 · CT.gov ↗
What to watch
2039 (1)
March 2039 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2039-03 · NCT07903506 · CT.gov ↗
What to watch
2042 (1)
February 2042 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2042-02 · NCT07887672 · CT.gov ↗
What to watch

See the full readout calendar ↗